ID   MKN28
AC   CVCL_1416
SY   MKN-28; MKN 28
DR   BTO; BTO:0002381
DR   CLO; CLO_0037142
DR   EFO; EFO_0002831
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 944
DR   BioSample; SAMN03151847
DR   cancercelllines; CVCL_1416
DR   Cell_Model_Passport; SIDM00260
DR   CGH-DB; 119-1
DR   CGH-DB; 9021-4
DR   ChEMBL-Cells; CHEMBL3307602
DR   ChEMBL-Targets; CHEMBL614353
DR   Cosmic; 801338
DR   Cosmic; 848146
DR   Cosmic; 848371
DR   Cosmic; 873710
DR   Cosmic; 875905
DR   Cosmic; 877041
DR   Cosmic; 887249
DR   Cosmic; 888826
DR   Cosmic; 897534
DR   Cosmic; 908139
DR   Cosmic; 918496
DR   Cosmic; 922694
DR   Cosmic; 926113
DR   Cosmic; 968348
DR   Cosmic; 983726
DR   Cosmic; 1066230
DR   Cosmic; 1067208
DR   Cosmic; 1090460
DR   Cosmic; 1093298
DR   Cosmic; 1223588
DR   Cosmic; 1436025
DR   Cosmic; 1460710
DR   Cosmic; 1482081
DR   Cosmic; 1627264
DR   Cosmic; 1995509
DR   Cosmic; 2036660
DR   Cosmic; 2069778
DR   Cosmic; 2823226
DR   Cosmic-CLP; 908139
DR   DepMap; ACH-002161
DR   EGA; EGAS00001000978
DR   GDSC; 908139
DR   GEO; GSM562396
DR   GEO; GSM1670112
DR   IARC_TP53; 972
DR   IARC_TP53; 21505
DR   JCRB; JCRB0253
DR   JCRB; NIHS0324
DR   JCRB; NIHS0325
DR   JCRB; FDSC0011
DR   KCLB; 80102
DR   LINCS_LDP; LCL-1922
DR   PharmacoDB; MKN28_937_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1416
DR   PubChem_Cell_line; CVCL_1416
DR   RCB; RCB1000
DR   Wikidata; Q54905823
RX   CelloPub=CLPUB00581;
RX   CelloPub=CLPUB00584;
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RX   PubMed=758928;
RX   PubMed=1370612;
RX   PubMed=1933850;
RX   PubMed=3962675;
RX   PubMed=3986962;
RX   PubMed=6862145;
RX   PubMed=9023415;
RX   PubMed=9290701;
RX   PubMed=11107048;
RX   PubMed=11314020;
RX   PubMed=15723654;
RX   PubMed=15767549;
RX   PubMed=15900046;
RX   PubMed=15901131;
RX   PubMed=20143388;
RX   PubMed=20164919;
RX   PubMed=22336246;
RX   PubMed=22490663;
RX   PubMed=23671654;
RX   PubMed=25960936;
RX   PubMed=27397505;
RX   PubMed=29435981;
RX   PubMed=29717028;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
WW   https://cellbank.nibiohn.go.jp/legacy/cellbank/qualitycontrol/identification/summary.htm
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a MKN74 derivative (PubMed=20143388).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: JFCR45 cancer cell line panel.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00328.
CC   Population: Japanese.
CC   Doubling time: 28-32 hours (PubMed=3962675); 28 hours (PubMed=29435981); 30-34 hours (CelloPub=CLPUB00584).
CC   HLA typing: A*31:01; B*51:01; C*03:04 (PubMed=9023415).
CC   HLA typing: B*51:01; C*03:04,03:04; DRB1*15:01,15:01 (PubMed=25960936).
CC   Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Leu (c.751A>C); ClinVar=VCV000182937; Zygosity=Unspecified (PubMed=1370612; PubMed=11107048; PubMed=15900046; PubMed=15901131; PubMed=22490663).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=83.28%; East Asian, South=16.71%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0324; true.
CC   Discontinued: JCRB; NIHS0325; true.
CC   Discontinued: JCRB; FDSC0011; true.
CC   Discontinued: RCB; RCB1000; true.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): Cosmic-CLP; JCRB; KCLB; RCB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 9,11
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 9
ST   FGA: 23
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 16,20
DI   NCIt; C5473; Gastric tubular adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2791 ! MKN74
SX   Male
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 42
//
RX   CelloPub=CLPUB00581;
RA   Hojo H.;
RT   "Establishment of cultured cell lines of human stomach cancer origin
RT   and their morphological characteristics.";
RL   Niigata Igakkai Zasshi 91:737-763(1977).
//
RX   CelloPub=CLPUB00584;
RA   Motoyama T., Hojo H., Suzuki T., Oboshi S.;
RT   "Evaluation of the regrowth assay method as an in vitro drug sensitivity
RT   test and its application to cultured human gastric cancer cell lines.";
RL   Acta Med. Biol. 27:49-63(1979).
//
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RA   Sekiguchi M., Suzuki T.;
RT   "Gastric tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York (1994).
//
RX   PubMed=758928; DOI=10.1038/bjc.1979.3;
RA   Kinjo M., Oka K., Naito S., Kohga S., Tanaka K., Oboshi S., Hayata Y.,
RA   Yasumoto K.;
RT   "Thromboplastic and fibrinolytic activities of cultured human cancer
RT   cell lines.";
RL   Br. J. Cancer 39:15-23(1979).
//
RX   PubMed=1370612; DOI=10.1016/S0006-291X(05)80133-0;
RA   Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O.,
RA   Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M.;
RT   "Missense mutations and a deletion of the p53 gene in human gastric
RT   cancer.";
RL   Biochem. Biophys. Res. Commun. 182:215-223(1992).
//
RX   PubMed=1933850;
RA   Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S.,
RA   Nakatani K., Nakano H., Sugimura T., Terada M.;
RT   "p53 gene mutations in gastric cancer metastases and in gastric cancer
RT   cell lines derived from metastases.";
RL   Cancer Res. 51:5800-5805(1991).
//
RX   PubMed=3962675; DOI=10.1111/j.1440-1827.1986.tb01461.x;
RA   Motoyama T., Hojo H., Watanabe H.;
RT   "Comparison of seven cell lines derived from human gastric
RT   carcinomas.";
RL   Acta Pathol. Jpn. 36:65-83(1986).
//
RX   PubMed=3986962; DOI=10.1093/carcin/6.4.549;
RA   Watatani M., Ikenaga M., Hatanaka T., Kinuta M., Takai S.-i., Mori T.,
RA   Kondo S.;
RT   "Analysis of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced DNA
RT   damage in tumor cell strains from Japanese patients and demonstration
RT   of MNNG hypersensitivity of Mer xenografts in athymic nude mice.";
RL   Carcinogenesis 6:549-553(1985).
//
RX   PubMed=6862145; DOI=10.20772/cancersci1959.74.2_240;
RA   Naito S., Inoue S., Kinjo M., Tanaka K.;
RT   "Thromboplastic and fibrinolytic activities of cultured human gastric
RT   cancer cell lines.";
RL   Gann 74:240-247(1983).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x;
RA   Yokozaki H.;
RT   "Molecular characteristics of eight gastric cancer cell lines
RT   established in Japan.";
RL   Pathol. Int. 50:767-777(2000).
//
RX   PubMed=11314020; DOI=10.1038/sj.onc.1204160;
RA   Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T.,
RA   Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.;
RT   "Alpha-fetoprotein producing gastric cancer lacks transcription factor
RT   ATBF1.";
RL   Oncogene 20:869-873(2001).
//
RX   PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x;
RA   Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H.,
RA   Okanoue T., Inazawa J.;
RT   "Screening of DNA copy-number aberrations in gastric cancer cell lines
RT   by array-based comparative genomic hybridization.";
RL   Cancer Sci. 96:100-110(2005).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y.,
RA   Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y.,
RA   Tomoda H., Yamori T., Tsuruo T.;
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D.-X., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//
RX   PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122;
RA   Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M.,
RA   Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S.,
RA   Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M.,
RA   Ishida M., Motoi F., Egawa S., Unno M., Horii A.;
RT   "DCK is frequently inactivated in acquired gemcitabine-resistant human
RT   cancer cells.";
RL   Biochem. Biophys. Res. Commun. 421:98-104(2012).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y.-H., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
//
RX   PubMed=29717028; DOI=10.1042/BSR20180277;
RA   Zhang Y.-Q., Yu S.-T., Zhang Z.-Z., Zhao G., Xu J.;
RT   "Long non-coding RNA AK096174 promotes cell proliferation and invasion
RT   in gastric cancer by regulating WDR66 expression.";
RL   Biosci. Rep. 38:BSR20180277.1-BSR20180277.12(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//